You are here: Industry Insights > Opdivo

News List

Bristol Myers says Opdivo performs well in kidney, lung cancer trials expresspharma
April 22, 2020
Opdivo is one of Bristol’s top-selling drugs, but sales of the drug have slowed in recent years as it has been eclipsed by Merck & Co’s rival drug Keytruda.
Infinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer pharmaceutical-business-review
March 30, 2020
Infinity Pharmaceuticals said that IPI-549 in combination with nivolumab (Opdivo) has been given the fast track designation from the US Food and Drug Administration (FDA).
U.S. Food and Drug Administration approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib worldpharmanews
March 12, 2020
Bristol Myers Squibb Company announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) to treat hepatocellular carcinoma (HCC) in patients ...
Opdivo, cabiralizumab combo falls short in pancreatic cancer pharmatimes
March 10, 2020
Bristol-Myers Squibb has revealed that its Phase II trial testing the combination of cabiralizumab with Opdivo (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer has fallen short of success.
Opdivo/Yervoy continues to impress in kidney cancer pharmatimes
March 10, 2020
Bristol-Myers Squibb has announced that its Opdivo (nivolumab) and Yervoy (ipilimumab) combo has demonstrated superior overall survival, complete response rates and objective response rates at 42 months ...
Compugen Announces Triple Combination Study to Evaluate COM701, Opdivo, TIGIT Inhibitor americanpharmaceuticalreview
March 09, 2020
Compugen announced its plan to initiate a Phase 1/2 study evaluating a triple combination of Compugen's COM701, an investigational anti-PVRIG antibody ...
BMS secures FDA priority review for NSCLC treatment combination pharmaceutical-technology
January 17, 2020
Bristol-Myers Squibb Company (BMS) has secured the US Food and Drug Administration (FDA) priority review for a drug combination to treat metastatic or recurrent non-small cell lung cancer (NSCLC).
WindMIL Announces Collaboration with Bristol-Myers Squibb to Evaluate MILs, Opdivo Combination americanpharmaceuticalreview
December 20, 2019
WindMIL Therapeutics has entered into a new clinical research collaboration with Bristol-Myers Squibb Company to evaluate the safety and efficacy of ...
Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo pharmaceutical-business-review
December 16, 2019
Vedanta Biosciences announced the initiation of a first-in-patient clinical study of VE800 in combination with Bristol-Myers Squibb's programmed death-1 (PD-1) immune ...
Another Anti-PD-L(1) Monoclonal Antibody Filed the IND Application in China to Join the 40+ Applicants! Sales of Keytruda to Rank Second in the World in 2019 PharmaSources/1°C
November 14, 2019
MSD released the Q3 financial report on Oct. 29, 2019. Its figures, especially the figures of its oncology business, were no longer shining, with keywords including Keytruda, Gardasil 9, and China.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page